Translational Neurophysiology
Pavia, 27100, Italy
Location status: Recruiting
NCT Number: NCT07664930
Pompe disease is traditionally considered a lysosomal myopathy. However, increasing experimental and clinical evidence suggests involvement of the entire motor unit, including motor neurons, peripheral nerves, neuromuscular junctions, and skeletal muscle. Respiratory impairment is a major cause of morbidity and mortality, and diaphragm dysfunction is frequently observed.
Clinical observations at IRCCS Fondazione Mondino have highlighted neurophysiological abnormalities of the phrenic nerve and diaphragm in patients with Pompe disease and respiratory involvement, sometimes occurring even in the absence of clinically significant limb muscle weakness. These findings suggest that respiratory motor unit dysfunction may represent an important component of the disease phenotype.
This observational study aims to systematically characterize phrenic nerve conduction parameters and diaphragm electromyographic findings in adult patients with genetically confirmed Pompe disease and in patients with unexplained respiratory failure. Retrospective and prospective clinical, neurophysiological, and respiratory data collected during routine clinical care will be analyzed to explore whether phrenic nerve and diaphragm abnormalities may serve as markers of respiratory motor unit involvement in Pompe disease.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Pavia, 27100, Italy
Location status: Recruiting
This is a non-interventional observational study with a mixed retrospective and prospective cohort design. No experimental treatments, additional diagnostic procedures, or study-specific interventions are introduced. All data derive exclusively from routine clinical evaluations performed as part of standard patient care. Two main populations are included: 1) Adult patients with genetically confirmed Pompe disease undergoing routine neurophysiological and respiratory assessments; 2) Patients with restrictive respiratory failure or unexplained hypoventilation who previously underwent phrenic nerve conduction studies and/or diaphragm electromyography as part of clinical workup, identified retrospectively. The retrospective component consists of systematic review of phrenic nerve conduction studies and diaphragm electromyography performed over previous years in patients with suspected neuromuscular respiratory failure. The prospective component involves standardized collection of neurophysiological and respiratory data obtained during routine follow-up of patients with confirmed Pompe disease.
Neurophysiological assessments include bilateral phrenic nerve motor conduction studies and evaluation of peripheral nerves and limb muscles. Diaphragm needle electromyography is performed only when clinically indicated. Respiratory evaluations include spirometry with forced vital capacity in seated and supine positions, maximal inspiratory and expiratory pressures (MIP/MEP), and, when clinically required, overnight ventilation studies.
The primary outcome is the characterization of phrenic nerve conduction parameters, including motor latency, compound muscle action potential amplitude, and presence or absence of diaphragmatic responses. Secondary outcomes include diaphragm electromyographic patterns, comparison between phrenic nerve and other peripheral nerves, and correlations between neurophysiological parameters and respiratory function.
Data are collected retrospectively from medical records and prospectively during routine clinical visits, pseudonymized, and analyzed descriptively and exploratorily. The study aims to improve characterization of respiratory motor unit involvement in Pompe disease and to evaluate the potential diagnostic contribution of phrenic nerve and diaphragm electrophysiology in patients with unexplained respiratory failure.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Age ≥ 18 years.
For the prospective cohort:
For the retrospective cohort:
Exclusion criteria
For the prospective cohort:
For the retrospective cohort:
Time frame: Baseline (at first available assessment, retrospective or prospective)
Phrenic nerve conduction parameter measured by bilateral nerve conduction studies
Time frame: Baseline (at first available assessment, retrospective or prospective)
Phrenic nerve conduction parameter assessed bilaterally by nerve conduction studies
Time frame: Baseline (at first available assessment, retrospective or prospective)
Phrenic nerve conduction parameter assessed bilaterally
Time frame: Baseline (at time of clinical assessment when EMG is performed)
Diaphragm electromyography pattern assessed when clinically indicated
Time frame: Baseline (at time of clinical assessment when EMG is performed)
Diaphragm electromyography pattern assessed when clinically indicated
Time frame: Baseline (at time of clinical assessment when EMG is performed)
Diaphragm electromyography pattern assessed when clinically indicated
Time frame: Baseline (at time of clinical assessment when EMG is performed)
Diaphragm electromyography pattern assessed when clinically indicated
Contact information is provided by the study sponsor or research team.
IRCCS National Neurological Institute "C. Mondino" Foundation
Other
Electrophysiological Study of the Phrenic Nerve and Diaphragm in Pompe Disease: Retrospective and Prospective Cohort Analysis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07123155
Brain Diseases, Brain Diseases, Metabolic
Irvine, California, United States
View Trial DetailsNCT00231400
Brain Diseases, Brain Diseases, Metabolic
Birmingham, Alabama, United States
View Trial DetailsNCT01665326
Brain Diseases, Brain Diseases, Metabolic
Durham, North Carolina, United States
View Trial DetailsNCT06121011
Brain Diseases, Brain Diseases, Metabolic
Little Rock, Arkansas, United States
View Trial Details